TY - JOUR
T1 - Association of Cerebrospinal Fluid Neurofilament Light Protein with Risk of Mild Cognitive Impairment among Individuals Without Cognitive Impairment
AU - Kern, Silke
AU - Syrjanen, Jeremy A.
AU - Blennow, Kaj
AU - Zetterberg, Henrik
AU - Skoog, Ingmar
AU - Waern, Margda
AU - Hagen, Clinton E.
AU - Van Harten, Argonde C.
AU - Knopman, David S.
AU - Jack, Clifford R.
AU - Petersen, Ronald C.
AU - Mielke, Michelle M.
N1 - Funding Information:
Funding/Support: This study was supported by funding from the NIH/National Institute on Aging grants U01 AG006786, R01 AG011378, R01 AG041851, and R01 AG049704; the GHR Foundation; and Roche Diagnostics Ltd. The study was made possible by the Rochester Epidemiology Project (grant R01 AG034676). The cerebrospinal fluid neurofilament light protein and neurogranin analyses were supported by grants from The Swedish Research Council (2013-2546), the European Research Council (681712), the Knut and Alice Wallenberg Foundation, Torsten Söderbergs Foundation at the Royal Swedish Academy of Sciences, Sahlgrenska University Hospital (ALF), Sahlgrenska University Hospital (ALFGBG-716681, ALFGBG-715841, ALFGBG-65930, and Higher Medical ALF-position), Torsten Söderberg Foundation, Swedish Alzheimer Foundation, and Hjärnfonden.
Funding Information:
served as a consultant on advisory boards for Alzheon, BioArctic, Biogen, Eli Lilly, Fujirebio Europe, IBL International, Merck, Novartis, Pfizer, and Roche Diagnostics and is a cofounder of Brain Biomarker Solutions in Gothenburg AB, a GU Venture–based platform company at the University of Gothenburg. Dr Zetterberg has served on advisory boards for Eli Lilly, Roche Diagnostics, and Wave; has received travel grants from Teva; and is a cofounder of Brain Biomarker Solutions. Dr Skoog has been an advisor and speaker for Takeda. Dr Knopman serves on a data safety monitoring board for Lundbeck Pharmaceuticals and for the Dominantly Inherited Alzheimer Network study; is an investigator in clinical trials sponsored by Biogen, Lilly Pharmaceuticals, and the Alzheimer’s Disease Cooperative Study; and receives research support from the National Institutes of Health (NIH). Dr Jack has provided consulting services for Eli Lilly and receives research funding from the NIH (grants R01 AG011378, U01 HL096917, U01 AG024904, R01 AG041851, R01 AG037551, R01 AG043392, and U01 AG006786) and the Alexander Family Alzheimer's Disease Research Professorship of the Mayo Clinic. Dr Petersen is a consultant for Roche Inc, Merck Inc, Biogen Inc, Genentech, Inc, and GE Healthcare. Dr Mielke served as a consultant to Eli Lilly and Lysosomal Therapeutics, Inc and receives research support from the NIH (grants R01 AG49704, P50 AG44170, U01 AG06786, and RF1 AG55151), the US Department of Defense (grant W81XWH-15-1), and unrestricted research grants from Biogen and Lundbeck.
Publisher Copyright:
© 2018 2018 American Medical Association. All rights reserved.
PY - 2019/2
Y1 - 2019/2
N2 - Importance: Accumulating data suggest that elevated cerebrospinal fluid (CSF) neurofilament light (NfL) and neurogranin (Ng) levels are associated with cognitive decline and may be useful markers of neurodegeneration. However, to our knowledge, previous studies have not assessed these CSF markers in the community, evaluated them with regards to risk of mild cognitive impairment (MCI), or compared their prognostic value with CSF total tau (T-tau) or phosphorylated tau (P-tau). Objective: To determine (1) whether CSF NfL and Ng levels were associated with risk of MCI, (2) the effect size of these markers compared with CSF T-tau or P-tau for risk of MCI, and (3) whether CSF amyloid-β (Aβ42) modified these associations. Design, Setting and Participants: The analyses included 648 participants without cognitive impairment who were enrolled into the prospective population-based Mayo Clinic Study of Aging between January 2004 and December 2015 with available CSF data and at least 1 follow-up visit. Participants were followed up for a median of 3.8 years (interquartile range, 2.6-5.4 years). The CSF NfL and Ng levels were measured using an in-house sandwich enzyme-linked immunosorbent assay. The CSF Aβ42, T-tau, and P-tau levels were measured with automated electrochemiluminescence immunoassays. Cox proportional hazards models, with age as the timescale, were used to assess the association between CSF NfL, Ng, Aβ42, T-tau, or P-tau with risk of MCI after adjusting for sex, education, apolipoprotein E genotype, and the Charlson comorbidity index. To examine CSF Aβ42 as an effect modifier, it was categorized into tertiles; the bottom tertile was defined as having elevated brain amyloid. Main Outcomes and Measures: Risk of MCI. Results: At baseline, the median age of the 648 participants without cognitive impairment was 72.3 years (range, 50.7-95.3 years) and 366 (56.5%) were men; 96 (14.8%) developed incident MCI. Compared with the bottom quartile, the top quartile of CSF NfL was associated with a 3.1-fold increased risk of MCI (hazard ratio, 3.13; 95% CI, 1.36-7.18) in multivariate models. Neither CSF T-tau, P-tau, nor Ng was associated with risk of MCI. There was no interaction between Aβ42 and CSF NfL for risk of MCI. Conclusions and Relevance: Elevated CSF NfL levels but not CSF T-tau, P-tau or Ng are a risk factor for MCI in a community population and are independent of brain amyloid..
AB - Importance: Accumulating data suggest that elevated cerebrospinal fluid (CSF) neurofilament light (NfL) and neurogranin (Ng) levels are associated with cognitive decline and may be useful markers of neurodegeneration. However, to our knowledge, previous studies have not assessed these CSF markers in the community, evaluated them with regards to risk of mild cognitive impairment (MCI), or compared their prognostic value with CSF total tau (T-tau) or phosphorylated tau (P-tau). Objective: To determine (1) whether CSF NfL and Ng levels were associated with risk of MCI, (2) the effect size of these markers compared with CSF T-tau or P-tau for risk of MCI, and (3) whether CSF amyloid-β (Aβ42) modified these associations. Design, Setting and Participants: The analyses included 648 participants without cognitive impairment who were enrolled into the prospective population-based Mayo Clinic Study of Aging between January 2004 and December 2015 with available CSF data and at least 1 follow-up visit. Participants were followed up for a median of 3.8 years (interquartile range, 2.6-5.4 years). The CSF NfL and Ng levels were measured using an in-house sandwich enzyme-linked immunosorbent assay. The CSF Aβ42, T-tau, and P-tau levels were measured with automated electrochemiluminescence immunoassays. Cox proportional hazards models, with age as the timescale, were used to assess the association between CSF NfL, Ng, Aβ42, T-tau, or P-tau with risk of MCI after adjusting for sex, education, apolipoprotein E genotype, and the Charlson comorbidity index. To examine CSF Aβ42 as an effect modifier, it was categorized into tertiles; the bottom tertile was defined as having elevated brain amyloid. Main Outcomes and Measures: Risk of MCI. Results: At baseline, the median age of the 648 participants without cognitive impairment was 72.3 years (range, 50.7-95.3 years) and 366 (56.5%) were men; 96 (14.8%) developed incident MCI. Compared with the bottom quartile, the top quartile of CSF NfL was associated with a 3.1-fold increased risk of MCI (hazard ratio, 3.13; 95% CI, 1.36-7.18) in multivariate models. Neither CSF T-tau, P-tau, nor Ng was associated with risk of MCI. There was no interaction between Aβ42 and CSF NfL for risk of MCI. Conclusions and Relevance: Elevated CSF NfL levels but not CSF T-tau, P-tau or Ng are a risk factor for MCI in a community population and are independent of brain amyloid..
UR - http://www.scopus.com/inward/record.url?scp=85056374657&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85056374657&partnerID=8YFLogxK
U2 - 10.1001/jamaneurol.2018.3459
DO - 10.1001/jamaneurol.2018.3459
M3 - Article
C2 - 30419087
AN - SCOPUS:85056374657
SN - 2168-6149
VL - 76
SP - 187
EP - 193
JO - JAMA neurology
JF - JAMA neurology
IS - 2
ER -